Navigation Links
Liponex Inc. Reports Further Analysis of CRD5 Phase I/II Clinical,Trial Data

any future results, performance or achievements expressed or implied by such forward-looking statements. Statements of "belief" with respect to reformulation, the undertaking of an additional clinical trial for CRD5 as well as CRD5's efficacy in raising HDL levels, are based primarily upon results derived to date from the Company's pre-clinical research and development and its results from completed Phase I and Phase I/II clinical trials. While the Company believes that it has reasonable scientific basis upon which to make such statements, it is not possible to predict whether a new therapeutic agent will be prove to be safe and/or effective in humans. The Company cannot guarantee that it actually will achieve the plans, intentions or expectations. and undue reliance should not be placed on those forward-looking statements. The Company does not expect to update forward-looking statements continually as conditions change. Investors are referred to the full discussion of risk factors associated with the Company's business contained in the Company's periodic regulatory filings, which can be found in the SEDAR database at www.sedar.com.

For further information: Investor Relations Joanna Longo The Equicom Group Inc. (416) 815-0700 ext. 233 jlongo@equicomgroup.com

Media Relations Linda Forrest inmedia Public Relations (613) 234-7227 ext. 234 lforrest@inmedia.com


'"/>




Page: 1 2 3

Related medicine technology :

1. Liponex Inc. Reports Phase I/II Clinical Trial Data for CRD5
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Liponex Inc Reports Further Analysis CRD5 Phase Clinical Trial Data
(Date:8/27/2014)... NORWALK, Conn. , Aug. 27, 2014  UBM ... , a leading online community for medical imaging professionals, ... Association for Medical Imaging Management,s 2014 Annual Meeting ... the conference coverage: , 11 Principles ... management can lead to greater profitability. , ...
(Date:8/27/2014)... , Aug. 27, 2014 /PRNewswire-iReach/ -- Emergency ... design, blended emergency medical training and response technologies, ... defibrillator) training from the Department of Homeland ... Reserve 81 st Regional Support Command ... contract includes nationwide CPR/AED/First Aid training. The Army ...
(Date:8/27/2014)... , Aug. 27, 2014   Auxilium Pharmaceuticals , Inc. ... biopharmaceutical company, today announced that certain members of the ... Healthcare Conference to be held September 8-10, 2014 in ... , Chief Executive Officer and President, is scheduled to ... portfolio at 10:55 a.m. ET on Wednesday, September 10, ...
Breaking Medicine Technology:Diagnostic Imaging Covers Association for Medical Imaging Management (AHRA) 2014 Meeting 2Diagnostic Imaging Covers Association for Medical Imaging Management (AHRA) 2014 Meeting 3Emergency University Equips Homeland Security, Army Reserve with SCA Response Program to Save Lives of Sudden Cardiac Arrest Victims 2Emergency University Equips Homeland Security, Army Reserve with SCA Response Program to Save Lives of Sudden Cardiac Arrest Victims 3Auxilium Pharmaceuticals, Inc. To Present At The Morgan Stanley Healthcare Conference 2Auxilium Pharmaceuticals, Inc. To Present At The Morgan Stanley Healthcare Conference 3
... Quark Pharmaceuticals, Inc., a pharmaceutical company engaged in ... it has dosed the first patient with recent onset ... ongoing Phase I study of QPI-1007, the Company,s proprietary ... The Phase I open-label, dose-escalation study was initiated ...
... PHILADELPHIA, Oct. 20 ERT (Nasdaq: ... for the third quarter 2010 on Thursday, November 4, 2010, ... host a conference call at 5:00 PM EDT that day. ... dial 1-800-860-2442 when calling within the United States or 1-412-858-4600 ...
Cached Medicine Technology:Quark Pharmaceuticals Doses First Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Patient in Stratum II of its Clinical Study of siRNA Drug Candidate QPI-1007 2Quark Pharmaceuticals Doses First Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Patient in Stratum II of its Clinical Study of siRNA Drug Candidate QPI-1007 3ERT to Announce Third Quarter 2010 Results on November 4, 2010 2
(Date:8/27/2014)... For nearly two decades, audiences around the world ... Deva Premal & Miten with their rapturous Nepali flute ... album in May, their 2014 MANTRAS FOR LIFE TOUR ... globe, including Russia, Ukraine, Israel, Australia, the U.S., Canada, ... new album and a new five-piece band, the love ...
(Date:8/27/2014)... positive hospital blood culture samples are discarded every day ... skin germs instead of specific disease-causing bacteria. , ... clinicians may be able to use the resistance profiles ... patients with antibiotics appropriate to their ailment, Tel Aviv ... Alon of TAU,s Sackler Faculty of Medicine and the ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 According ... Market Research "Ablation Technologies Market (Applications: Cardiovascular, Gynecology, ... Electrical, Ultrasound, Microwave, Cryotherapy) - Global Industry Analysis, ... 2020," the global ablation technologies market was valued ... estimated to reach a market worth USD 10,611 ...
(Date:8/27/2014)... NH 8/27/14)Dartmouth cancer researchers developed and tested an ... environmental interactions that contribute to disease as published ... , The approach fills a gap in current ... complex interactions among genetic and environmental factors. When ... interactions versus those that reflect chance combinations among ...
(Date:8/27/2014)... 2014 Nava Beauty Store and Spa aims ... patrons from those seeking luxury care products to the everyday ... high end luxurious brands like Valmont and Elemis to cater ... brands like Dermalogica and Bliss to provide easy to use ... also offer purely organic skin care products such as Jurlique, ...
Breaking Medicine News(10 mins):Health News:Deva Premal & Miten's Mantras For Life Tour Announced 2Health News:Deva Premal & Miten's Mantras For Life Tour Announced 3Health News:'Junk' blood tests may offer life-saving information 2Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 2Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 3Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 4Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 5Health News:Dartmouth isolates environmental influences in genome-wide association studies 2Health News:Nava Beauty Store Announce Grand Opening in Great Neck, New York 2
... in the United States who undergo surgery to have ... a recent study shows that men who have their ... cancer returns . ,Researchers studied more than 500 ... study first had a radical prostatectomy and also underwent ...
... is the most common bacterial illness in children and ... of children may be getting treated unnecessarily with antibiotics ... they don’t need them may build up antibiotic resistance, ... a more serious infection. ,According to the new ...
... that certain hormones in the body may yield a ... events and death in people with no symptoms. Researchers ... the current standards used to diagnose heart failure. ... the participants’ blood looking for specific substances and compared ...
... their risk of birth defects. Now, new research shows ... say about 31,000 stroke-related deaths and about 17,000 heart ... fortification was implemented. ,Folic acid lowers homocysteine levels. ... risk for stroke and heart disease. Specialists from the ...
... new study shows the use of antibacterial products, such ... reduce the risk of infectious// disease symptoms in the ... households in New York with at least one preschool-age ... household cleaning and personal hygiene products that contained antibacterial ...
... study suggests drinking extra fluids may do more harm ... ,Researchers examined results from previous studies to determine if ... safe. Previous data has shown during a respiratory infection, ... large amounts of a specific hormone that conserves water. ...
Cached Medicine News:
... High Throughput Screening (UHTS), Analyst GT ... Allows for smooth transfer of assays ... sharing all the detection modalities of ... fluorescence polarization, time-resolved fluorescence, luminescence, absorbance, ...
... Ultra High Throughput Screening (UHTS), Analyst ... performance. Allows for smooth transfer of ... by sharing all the detection modalities ... intensity, fluorescence polarization, time-resolved fluorescence, luminescence, ...
... exclusively for cell-based assays, the NOVOstar provides ... to the flexibility of an on-board reagent ... plate to plate or from three reagent ... the unit has two injectors that can ...
... cDNA and Oligonucleotides The Tecan GENios ... variety applications that are quantified by Fluorescence, Absorbance ... assays in Microplate formats from 6 to ... Cuvettes Independent whether you have to quantitate ...
Medicine Products: